ArticleAmerican journal of physiology. Renal physiology2020
A role for tubular Na
Open access · greenAbstract read
In one paragraph
Article in American journal of physiology. Renal physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 3 pooled it
16.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 3 syntheses or guidelines pooled it, 196 citations in OpenAlex.
- SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Pooled it
- Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease.Frontiers in immunology · 2023Pooled it
- Pooled it
- Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial.Nature medicine · 2025Trial
- Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme.European heart journal · 2022Trial
- Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?The Journal of clinical endocrinology and metabolism · 2022Trial
- Renal gluconeogenesis: a key metabolic hub in health and kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- Metabolic control by liver-kidney crosstalk and glucagon in health and disease.Nature reviews. Nephrology · 2026Review
- The Potential Role of SGLT2 Inhibitors in Cushing's Disease.Diabetes, obesity & metabolism · 2026Review
- Insulin resistance and hyperinsulinaemia in kidney disease: mechanisms and metabolic effects.Nature reviews. Nephrology · 2026Review
- Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk.Journal of translational medicine · 2026Review
- Sodium-Glucose Cotransporter 2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease: Mechanistic Insights and Therapeutic Promise.Journal of the American Society of Nephrology : JASN · 2026Review
- Cellular microenvironment of erythropoietin-producing cells in hypoxic and injured mouse kidneys.Experimental physiology · 2026Article
- Empagliflozin preserves cardiac function and modulates metabolism in a mouse model of Duchenne muscular dystrophy.bioRxiv : the preprint server for biology · 2026Article
- Review
- Sodium-Glucose Cotransporter 2 Inhibitors Prevent Nephrolithiasis in Patients with Diabetes: A TriNetX-Based Real-World Global Comparison.Kidney360 · 2026Article
- Repurposing SGLT2 Inhibitors for Cirrhotic Ascites: From Mechanistic Research to Clinical Exploration.Journal of clinical and translational hepatology · 2026Review
- SGLT2 inhibitors and acute kidney injury.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- Current understanding of sodium-glucose transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome.Frontiers in pharmacology · 2026Review
- Microbes and GFR in Health and CKD in Mice.Journal of the American Society of Nephrology : JASN · 2026Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Akira OnishiDepartment of Medicine, University of California-San Diego and Veterans Affairs San Diego Healthcare System, San Diego, California.
Yiling FuDepartment of Medicine, University of California-San Diego and Veterans Affairs San Diego Healthcare System, San Diego, California.
Rohit PatelDepartment of Medicine, University of California-San Diego and Veterans Affairs San Diego Healthcare System, San Diego, California.
Manjula DarshiCenter for Renal Precision Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Maria Crespo-MasipDepartment of Medicine, University of California-San Diego and Veterans Affairs San Diego Healthcare System, San Diego, California.
Winnie HuangDepartment of Medicine, University of California-San Diego and Veterans Affairs San Diego Healthcare System, San Diego, California.
Panai SongDepartment of Medicine, University of California-San Diego and Veterans Affairs San Diego Healthcare System, San Diego, California.
Brent FreemanDepartment of Medicine, University of California-San Diego and Veterans Affairs San Diego Healthcare System, San Diego, California.
Young Chul KimDepartment of Medicine, University of California-San Diego and Veterans Affairs San Diego Healthcare System, San Diego, California.
Manoocher SoleimaniDivision of Nephrology, University of New Mexico, Albuquerque, New Mexico.
Kumar SharmaCenter for Renal Precision Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Scott Culver ThomsonDepartment of Medicine, University of California-San Diego and Veterans Affairs San Diego Healthcare System, San Diego, California.
Volker VallonDepartment of Medicine, University of California-San Diego and Veterans Affairs San Diego Healthcare System, San Diego, California.
University of California, San Diego · USVA San Diego Healthcare System · USThe University of Texas Health Science Center at San Antonio · USUniversity of New Mexico · US
Funding
UAB-UCSD O'Brien Core Center for Acute Kidney Injury ResearchP30DK079337 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AGARWAL, ANUPAM · 2008 to 2022
$18.3MGlomerular and Tubular Function in the Diabetic KidneyR01DK112042 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI SCOTT Culver THOMSON, Volker Vallon · 2017 to 2026
$4.1MThe Contribution of Kidney Disease to Age-Associated Cognitive DeclineRF1AG061296 · NIA · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI MAHER, PAMELA ANNE · 2019 to 2019
$3.2MRole of tubuloglomerular feedback in the development of hypertension in diabetesR01HL142814 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI LIU, RUISHENG · 2019 to 2022
$2.4MUnraveling Kidney Physiology, Pathophysiology & Therapeutics: A Modeling ApproachR01DK106102 · NIDDK · DUKE UNIVERSITY · PI LAYTON, ANITA · 2016 to 2019
$1.4MHHS | NIH | National Heart, Lung, and Blood Institute (NHBLI) R01-HL142814HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01-DK106102HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01-DK112042HHS | NIH | National Institute on Aging (U.S. National Institute on Aging) RF1-AG061296NHLBI NIH HHS R01 HL142814NIA NIH HHS RF1 AG061296NIDDK NIH HHS P30 DK079337NIDDK NIH HHS R01 DK106102NIDDK NIH HHS R01 DK112042
Abstract
Inhibitors of proximal tubular Na
Indexed as
Acid-Base EquilibriumAnimalsBenzhydryl CompoundsBlood GlucoseBlood PressureDiabetes MellitusDisease Models, AnimalGlucosidesGlycosuriaKidney Tubules, ProximalMaleMice, Inbred C57BLMice, KnockoutNatriuresisNatriuretic AgentsPhosphorylationBenzhydryl CompoundsBlood GlucoseempagliflozinGlucosidesNatriuretic AgentsSlc5a2 protein, mouseSlc9a3 protein, mouseSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsSodium-Hydrogen Exchanger 3azelaic acidkidney metabolismNa+-glucose cotransporter 2 inhibitorNa+/H+ exchangernatriuresisproximal tubule
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.